ASND vs GMAB

Ascendis Pharma A/S and Genmab A/S, both Healthcare

Genmab A/S is the larger company at $16B against $15B. Over the past year GMAB returned +49% against +32% for ASND. Ryufin's sector-relative Smart Score puts GMAB ahead, 9/10 against 8/10.

Ascendis Pharma A/S and Genmab A/Scompared on valuation, return and Ryufin’s Smart Score
FigureASNDGMAB
Last close$250$33.75
Market cap$15B$16B
1-year return+32%+49%
5-year return+108%-25%
Ryufin Smart Scoresector-relative, 1–108/109/10

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

Ascendis Pharma A/S

Revenue of $248M in Q4 2025, net income null.

ASND overviewrevenue and segmentsvaluation

Genmab A/S

Revenue of $12B in H2 2024, net income $5.1B.

GMAB overviewrevenue and segmentsvaluation

Open these two in the interactive comparison to add more names, change the period or read the correlation.